Mondo Visione Worldwide Financial Markets Intelligence

FTSE Mondo Visione Exchanges Index:

News Centre

  • ISDA derivatiViews: Next Steps For China’s Derivatives Market

    Date 20/12/2021

    In recent years, Chinese authorities have made incremental progress in developing the country’s derivatives markets and removing barriers to international participation. In 2021, they took a major step forward with draft legislation that would recognize the enforceability of close-out netting. With this seismic development now within reach, it is time to consider what further steps will be needed to promote a safe, robust and efficient derivatives market in China.

  • SEC Charges Five Russians In $80 Million Hacking And Trading Scheme

    Date 20/12/2021

    The Securities and Exchange Commission today announced fraud charges against five Russian nationals for engaging in a multi-year scheme to profit from stolen corporate earnings announcements obtained by hacking into the systems of two U.S.-based filing agent companies before the announcements were made public. The filing agents assist publicly traded companies with the preparation and filing of periodic reports with the SEC, including quarterly reports containing earnings information.

  • Government Of Ontario: Capital Markets Act (CMA) Consultation Extended To February 18

    Date 20/12/2021

    The Government of Ontario has published draft legislation for the new Capital Markets Act (CMA), accompanied by a policy commentary document and table of concordance. This draft legislation is part of the Capital Markets Modernization Review, and is intended as a vehicle to adopt a number of the Taskforce’s modernization recommendations.

  • SEC Charges Clinical Drug Trial Investigator With Insider Trading

    Date 20/12/2021

    The Securities and Exchange Commission today announced charges against Daniel V.T. Catenacci for insider trading in the securities of biotechnology company Five Prime Therapeutics, Inc. in advance of the company’s November 10, 2020 announcement that it had achieved positive drug trial results for its flagship cancer drug Bemarituzumab.

  • BOX Exchange: January 2022 Fee Change

    Date 20/12/2021

    BOX Exchange LLC is amending Section VIII (Participant Fees) of the BOX Fee Schedule.1 Specifically, BOX Options Market is adopting monthly Electronic Market Maker Trading Permit Fees as follows: